retatrutide glp-1 medication Some Providers Prescribe Unapproved for Weight Loss at Alarming Rate Retatrutide, a GIP, GLP-1 and

Ethics declarations Competing interests KGW and VJNB are co-founders and shareholders of Aprea Therapeutics AB, a company that develops novel p53-based cancer therapy

Heres what happened: Starting point: Weight: 89.5kg Body fat: 15% Fat mass: 13.4kg Muscle mass: 73.5kg Visceral fat: Level 5 (relatively low) After 3 months: Weight: 77kg Body fat: 8.3% Fat mass: 6.8kg Muscle mass: 71.1kg Visceral fat: Level 2 Total changes: Weight lost: 12.5kg Fat lost: 6.6kg (over a stone of pure fat) Muscle lost: 2.4kg (mostly water, not actual muscle tissue) Visceral fat reduction: 60% Cardiovascular fitness: VO2 max improved from 51 54 (significant increase) Strength: Lost 10-15% on main lifts (bench press, squats, pull-ups)

GLP-1s are meant to be used along with diet and exercise

Documentation Buyers Should Prepare Before Quotation For faster pricing, prepare target market, expected bottle count, label language, ingredient direction, serving count, packaging style, certification needs, and shipment destination

Call/Text us at 312.312.7873 or book your appointment online today

For instructions, review the insert that comes with your carton of semaglutide